Mann K, Saller B, Hoermann R
Medical Department II, Klinikum Grosshadern, University of Munich, DE.
Scand J Clin Lab Invest Suppl. 1993;216:97-104.
Recent advances in our understanding of hCG/hCG beta synthesis by trophoblastic and nontrophoblastic tissues together with improved techniques for measuring hCG have helped to define the role of hCG as a clinical marker. HCG determination by sensitive immunometric assay enables detection of hCG immunoreactivity in normal men and women. It facilitates early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. For diagnosis and follow-up of patients with testicular cancer, a method measuring both hCG and hCG beta or separate methods for each component are recommended, because a significant portion of seminoma exclusively secrete free hCG beta. Also, hCG beta production by other than trophoblastic malignancies has been well recognized. A possible clinical use of hCG beta as a marker of cancers of the bladder, pancreas or biliary tract is currently debated.
我们对滋养层和非滋养层组织合成人绒毛膜促性腺激素（hCG）/hCGβ的最新认识进展，以及测量hCG的技术改进，有助于明确hCG作为临床标志物的作用。通过灵敏的免疫分析测定hCG能够检测正常男性和女性体内的hCG免疫反应性。它有助于早期发现正常妊娠，并对各种妊娠相关疾病的诊断有重要意义，如异位妊娠、自然流产、葡萄胎、绒毛膜癌或21三体综合征。此外，测定该标志物对指导睾丸癌的治疗干预非常有帮助。对于睾丸癌患者的诊断和随访，建议采用同时检测hCG和hCGβ的方法或分别检测各组分的方法，因为相当一部分精原细胞瘤仅分泌游离的hCGβ。此外，非滋养层恶性肿瘤产生hCGβ也已得到充分认识。目前正在讨论hCGβ作为膀胱癌、胰腺癌或胆管癌标志物的可能临床应用。
